TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Insider Jodi Devlin Sells 4,764 Shares of Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) insider Jodi Devlin sold 4,764 shares of the business’s stock in a transaction on Monday, May 19th. The stock was sold at an average price of $5.18, for a total value of $24,677.52. Following the transaction, the insider now directly owns 52,764 shares in the company, valued at $273,317.52. This trade represents a 8.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

TriSalus Life Sciences Trading Up 1.3%

TLSI stock opened at $5.44 on Thursday. The company has a market capitalization of $175.56 million, a PE ratio of -2.18 and a beta of 0.50. TriSalus Life Sciences, Inc. has a 12-month low of $3.50 and a 12-month high of $9.95. The business’s fifty day moving average price is $5.40 and its 200 day moving average price is $5.02.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.13). The company had revenue of $9.17 million during the quarter, compared to analysts’ expectations of $9.04 million. During the same quarter in the previous year, the company earned ($0.60) EPS. Research analysts predict that TriSalus Life Sciences, Inc. will post -1.55 EPS for the current fiscal year.

Institutional Investors Weigh In On TriSalus Life Sciences

Institutional investors and hedge funds have recently modified their holdings of the company. Charles Schwab Investment Management Inc. purchased a new stake in shares of TriSalus Life Sciences in the 1st quarter valued at $55,000. Renaissance Technologies LLC purchased a new stake in TriSalus Life Sciences during the 4th quarter worth about $67,000. Connective Capital Management LLC purchased a new stake in TriSalus Life Sciences during the 4th quarter worth about $140,000. Northern Trust Corp increased its holdings in TriSalus Life Sciences by 22.7% during the 4th quarter. Northern Trust Corp now owns 32,112 shares of the company’s stock worth $161,000 after purchasing an additional 5,936 shares during the period. Finally, Goldman Sachs Group Inc. purchased a new stake in TriSalus Life Sciences during the 1st quarter worth about $187,000. Hedge funds and other institutional investors own 2.58% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on TLSI shares. Roth Mkm restated a “buy” rating and issued a $11.00 target price on shares of TriSalus Life Sciences in a research report on Friday, January 24th. Lake Street Capital started coverage on TriSalus Life Sciences in a research report on Thursday, February 13th. They issued a “buy” rating and a $10.00 target price on the stock. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $11.00 target price on shares of TriSalus Life Sciences in a research report on Friday, March 28th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, TriSalus Life Sciences presently has an average rating of “Buy” and an average target price of $10.93.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.